MedTrace Logo

Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)

NCT01434849 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-11-15

No results posted yet for this study

Summary

The purpose of this trial is to see if a topical beta blocker is effective in preventing the proliferation of infantile hemangioma.

Conditions

  • Infantile Hemangioma
  • Very Low Birth Weight Infants

Interventions

DRUG

topical 0.5% Timolol maleate

topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily

DRUG

Control (placebo) group

Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily

Sponsors & Collaborators

  • Alice K. Gong

    lead OTHER

Principal Investigators

  • Alice K Gong, M.D. · The University of Texas Health Science Center at San Antonio

  • Alice K Gong, MD · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Max Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01434849 on ClinicalTrials.gov